Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Biochemical features of a catalytic antibody light chain, 22F6, prepared from human lymphocytes.

Hifumi E, Fujimoto N, Arakawa M, Saito E, Matsumoto S, Kobayashi N, Uda T.

J Biol Chem. 2013 Jul 5;288(27):19558-68. doi: 10.1074/jbc.M113.454579. Epub 2013 May 15.

2.

Biochemical features and antiviral activity of a monomeric catalytic antibody light-chain 23D4 against influenza A virus.

Hifumi E, Arakawa M, Matsumoto S, Yamamoto T, Katayama Y, Uda T.

FASEB J. 2015 Jun;29(6):2347-58. doi: 10.1096/fj.14-264275. Epub 2015 Feb 20.

3.

Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE Jr.

Nature. 2008 Sep 25;455(7212):532-6. doi: 10.1038/nature07231. Epub 2008 Aug 17. Erratum in: Nature. 2012 Oct 25;490(7421):570.

4.

Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs.

Seibert CW, Rahmat S, Krause JC, Eggink D, Albrecht RA, Goff PH, Krammer F, Duty JA, Bouvier NM, GarcĂ­a-Sastre A, Palese P.

J Virol. 2013 Jul;87(14):7793-804. doi: 10.1128/JVI.00979-13. Epub 2013 May 22.

5.

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J.

PLoS One. 2008;3(12):e3942. doi: 10.1371/journal.pone.0003942. Epub 2008 Dec 16.

6.

Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics.

Hifumi E, Honjo E, Fujimoto N, Arakawa M, Nishizono A, Uda T.

FASEB J. 2012 Apr;26(4):1607-15. doi: 10.1096/fj.11-195339. Epub 2011 Dec 28.

PMID:
22205784
7.
8.

Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.

Nosaka N, Yashiro M, Yamada M, Fujii Y, Tsukahara H, Liu K, Nishibori M, Matsukawa A, Morishima T.

Crit Care. 2015 Jun 11;19:249. doi: 10.1186/s13054-015-0983-9.

9.

Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV).

Burioni R, Canducci F, Mancini N, Clementi N, Sassi M, De Marco D, Diotti RA, Saita D, Sampaolo M, Sautto G, Pianezze M, Clementi M.

Virology. 2010 Mar 30;399(1):144-52. doi: 10.1016/j.virol.2009.12.014. Epub 2010 Jan 22.

10.

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H.

Sci Transl Med. 2013 Aug 28;5(200):200ra114. doi: 10.1126/scitranslmed.3006366.

11.

Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.

Fukushi M, Yamashita M, Miyoshi-Akiyama T, Kubo S, Yamamoto K, Kudo K.

PLoS One. 2012;7(8):e42419. doi: 10.1371/journal.pone.0042419. Epub 2012 Aug 1.

12.

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.

Yu J, Wang D, Jin J, Xu J, Li M, Wang H, Dou J, Zhou C.

Antiviral Res. 2016 Mar;127:68-78. doi: 10.1016/j.antiviral.2016.01.011. Epub 2016 Jan 21.

PMID:
26802558
13.

Antiviral effect of methylated flavonol isorhamnetin against influenza.

Abdal Dayem A, Choi HY, Kim YB, Cho SG.

PLoS One. 2015 Mar 25;10(3):e0121610. doi: 10.1371/journal.pone.0121610. eCollection 2015.

14.
15.

Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice.

Kash JC, Xiao Y, Davis AS, Walters KA, Chertow DS, Easterbrook JD, Dunfee RL, Sandouk A, Jagger BW, Schwartzman LM, Kuestner RE, Wehr NB, Huffman K, Rosenthal RA, Ozinsky A, Levine RL, Doctrow SR, Taubenberger JK.

Free Radic Biol Med. 2014 Feb;67:235-47. doi: 10.1016/j.freeradbiomed.2013.10.014. Epub 2013 Oct 17.

16.

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.

De Marco D, Clementi N, Mancini N, Solforosi L, Moreno GJ, Sun X, Tumpey TM, Gubareva LV, Mishin V, Clementi M, Burioni R.

PLoS One. 2012;7(4):e34415. doi: 10.1371/journal.pone.0034415. Epub 2012 Apr 4.

17.

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y.

J Virol. 2013 Jul;87(14):7874-81. doi: 10.1128/JVI.00076-13. Epub 2013 May 8.

18.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

19.

Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors.

Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, Kuhara M, Yamamoto N, Okuno Y, Ikuta K.

Biochem Biophys Res Commun. 2009 Sep 11;387(1):180-5. doi: 10.1016/j.bbrc.2009.06.151. Epub 2009 Jul 4.

PMID:
19580789
20.

Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C.

Kim EH, Pascua PN, Song MS, Baek YH, Kwon HI, Park SJ, Lim GJ, Kim SM, Decano A, Lee KJ, Cho WK, Ma JY, Choi YK.

Antiviral Res. 2013 Jun;98(3):386-93. doi: 10.1016/j.antiviral.2013.04.006. Epub 2013 Apr 13.

PMID:
23588232

Supplemental Content

Support Center